DOCSLIB.ORG

Haloperidol Haloxazolam Homochlorcyclizine Hydrochloride

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Haloperidol Haloxazolam Homochlorcyclizine Hydrochloride 1586 Ultraviolet-visible Reference Spectra JP XV Haloperidol A solution prepared as follows: Dissolve 30 mg in 100 mL of 2-propanol. To 5 mL of this solution add 10 mL of 0.1 mol/L hydrochloric acid TS and 2-propanol to make 100 mL. Haloxazolam A solution in methanol (1 in 100,000) Homochlorcyclizine Hydrochloride Asolutionin0.1mol/LhydrochloricacidTS(1in100,000) JP XV Ultraviolet-visible Reference Spectra 1587 Hydralazine Hydrochloride An aqueous solution (1 in 100,000) Hydrochlorothiazide A solution prepared as follows: Dissolve 12 mg in 100 mL of sodium hydroxide TS. 10 mL of this solution add water to make 100 mL. Hydrocotarnine Hydrochloride Hydrate An aqueous solution (1 in 10,000) 1588 Ultraviolet-visible Reference Spectra JP XV Hydroxocobalamin Acetate A solution in acetic acid-sodium acetate buffer solution, pH 4.5 (1 in 50,000) Hydroxyzine Hydrochloride A solution in methanol (1 in 100,000) Hydroxyzine Pamoate A solution prepared as follows: Evaporate 2 mL of the sample solution obtained in the Identification (1) on a water bath to dryness, and dissolve the residue in 0.1 mol/L hydrochloric acid TS to make 500 mL. JP XV Ultraviolet-visible Reference Spectra 1589 Hymecromone A solution in ethanol (99.5) (1 in 250,000) Ibuprofen A solution in dilute sodium hydroxide TS (3 in 20,000) Idarubicin Hydrochloride A solution in methanol (1 in 100,000) 1590 Ultraviolet-visible Reference Spectra JP XV Idoxuridine A solution in 0.01 mol/L sodium hydroxide TS (1 in 25,000) Ifenprodil Tartrate A solution in methanol (1 in 100,000) Imipenem Hydrate A solution in 0.1 mol/L 3-(N-morpholino)propanesulfonic acid buffer solution, pH 7.0 (1 in 50,000) JP XV Ultraviolet-visible Reference Spectra 1591 Imipramine Hydrochloride A solution prepared as follows: Dissolve 5 mg in 250 mL of 0.01 mol/L hydrochloric acid TS Indenolol Hydrochloride 1 An aqueous solution (1 in 50,000) Indenolol Hydrochloride 2 An aqueous solution (1 in 10,000) 1592 Ultraviolet-visible Reference Spectra JP XV Indigocarmine A solution prepared as follows: Dissolve 0.1 g in 100 mL of an aqueous solution of ammonium acetate (1 in 650). To 1 mL of this solution add the aqueous solution of ammonium acetate (1 in 650) to make 100 mL. Indometacin A solution prepared as follows: Dissolve 2 mg in 200 mL of methanol. Ipratropium Bromide Hydrate A solution in 0.01 mol/L hydrochloric acid TS (3 in 2000) JP XV Ultraviolet-visible Reference Spectra 1593 Isoniazid A solution prepared as follows: To 5 mL of an aqueous solution (1 in 10,000) add 1 mL of 0.1 mol/L hydrochloric acid TS and water to make 50 mL. l-Isoprenaline Hydrochloride Asolutionin0.1mol/LhydrochloricacidTS(1in20,000) Josamycin A solution in methanol (1 in 100,000) 1594 Ultraviolet-visible Reference Spectra JP XV Josamycin Propionate A solution in methanol (1 in 100,000) Ketamine Hydrochloride Asolutionin0.1mol/LhydrochloricacidTS(1in3000) Ketoprofen A solution in methanol (1 in 200,000) JP XV Ultraviolet-visible Reference Spectra 1595 Ketotifen Fumarate A solution in methanol (1 in 50,000) Kitasamycin A solution in methanol (1 in 40,000) Kitasamycin Acetate A solution in methanol (1 in 40,000) 1596 Ultraviolet-visible Reference Spectra JP XV Kitasamycin Tartrate A solution in methanol (1 in 40,000) Latamoxef Sodium An aqueous solution (3 in 100,000) Levallorphan Tartrate A solution in 0.01 mol/L hydrochloric acid TS (1 in 10,000) JP XV Ultraviolet-visible Reference Spectra 1597 Levodopa A solution in 0.001 mol/L hydrochloric acid TS (3 in 100,000) Levothyroxine Sodium Hydrate A solution in dilute sodium hydroxide TS (1 in 10,000) Lidocaine A solution prepared as follows: Dissolve 0.04 g in 10 mL of 1 mol/L hydrochloric acid TS and water to make 100 mL. 1598 Ultraviolet-visible Reference Spectra JP XV Limaprost Alfadex A solution prepared as follows: To 10 mL of a solution in dilute ethanol (3 in 10,000) add 1 mL of potassium hydroxide-ethanol TS, and allow to stand for 15 minutes. Liothyronine Sodium A solution in ethanol (95) (1 in 10,000) Lisinopril Hydrate A solution in methanol (1 in 1000) JP XV Ultraviolet-visible Reference Spectra 1599 Lorazepam A solution in ethanol (95) (1 in 200,000) Loxoprofen Sodium Hydrate An aqueous solution (1 in 55,000) Lysozyme Hydrochloride A solution in acetate buffer solution, pH 5.4 (1 in 10,000) 1600 Ultraviolet-visible Reference Spectra JP XV Maprotiline Hydrochloride A solution in methanol (1 in 10,000) Meclofenoxate Hydrochloride An aqueous solution (1 in 10,000) Mecobalamin 1 A solution in hydrochloric acid-potassium chloride buffer solution, pH 2.0 (1 in 20,000) JP XV Ultraviolet-visible Reference Spectra 1601 Mecobalamin 2 A solution in phosphate buffer solution, pH 7.0 (1 in 20,000) Medazepam A solution in methanol (1 in 100,000) Mefenamic Acid A solution prepared as follows: Dissolve 7 mg in a solution of hydrochloric acid in methanol (1 in 1000) to make 500 mL. 1602 Ultraviolet-visible Reference Spectra JP XV Mefloquine Hydrochloride A solution in methanol (1 in 25,000) Mefruside A solution in methanol (1 in 40,000) Melphalan A solution in methanol (1 in 10,000) JP XV Ultraviolet-visible Reference Spectra 1603 Mepenzolate Bromide A solution in 0.01 mol/L hydrochloric acid TS (1 in 2000) Mepivacaine Hydrochloride An aqueous solution (1 in 2500) Mequitazine A solution in ethanol (95) (1 in 250,000) 1604 Ultraviolet-visible Reference Spectra JP XV Mercaptopurine Hydrate Asolutionin0.1mol/LhydrochloricacidTS(1in200,000) Mestranol A solution in ethanol (99.5) (1 in 10,000) Metformin Hydrochloride An aqueous solution (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1605 Methotrexate A solution prepared as follows: Dissolve 1 mg in 100 mL of 0.1 mol/L hydrochloric acid TS. Methoxsalen A solution in ethanol (95) (1 in 200,000) Methyldopa Hydrate Asolutionin0.1mol/LhydrochloricacidTS(1in25,000) 1606 Ultraviolet-visible Reference Spectra JP XV dl-Methylephedrine Hydrochloride An aqueous solution (1 in 2000) Methylergometrine Maleate The colored solution obtained in the Assay Methylprednisolone A solution in methanol (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1607 Methylprednisolone Succinate A solution in methanol (1 in 50,000) Methyltestosterone A solution in ethanol (95) (1 in 100,000) Meticrane A solution in methanol (3 in 10,000) 1608 Ultraviolet-visible Reference Spectra JP XV Metildigoxin A solution in methanol (1 in 50,000) Metoclopramide A solution prepared as follows: Dissolve 0.1 g in 1 mL of 1 mol/L hydrochloric acid TS, and add water to make 100 mL. To 1 mL of this solution add water to make 100 mL. Metoprolol Tartrate A solution in ethanol (95) (1 in 10,000) JP XV Ultraviolet-visible Reference Spectra 1609 Metronidazole Asolutionin0.1mol/LhydrochloricacidTS(1in100,000) Metyrapone Asolutionin0.5mol/LsulfuricacidTS(1in100,000) Mexiletine Hydrochloride A solution in 0.01 mol/L hydrochloric acid TS (1 in 2000) 1610 Ultraviolet-visible Reference Spectra JP XV Miconazole A solution in methanol (1 in 2500) Miconazole Nitrate A solution in methanol (1 in 2500) Midecamycin A solution in methanol (1 in 50,000) JP XV Ultraviolet-visible Reference Spectra 1611 Midecamycin Acetate A solution in methanol (1 in 50,000) Minocycline Hydrochloride A solution in a solution of hydrochloric acid in methanol (19 in 20,000) (1 in 62,500) Mitomycin C An aqueous solution (1 in 100,000) 1612 Ultraviolet-visible Reference Spectra JP XV Morphine Hydrochloride Hydrate 1 An aqueous solution (1 in 10,000) Morphine Hydrochloride Hydrate 2 A solution in dilute sodium hydroxide TS (1 in 10,000) Nadolol A solution in methanol (1 in 5000).
Load more

Recommended publications
  • Anaphylactic Microshock of the Guinea-Pig by H
    Brit. J. Pharmacol. (1963), 21, 414-418. THE EFFECT OF SOME NEW ANTIHISTAMINES ON THE ANAPHYLACTIC MICROSHOCK OF THE GUINEA-PIG BY H. HERXHEIMER AND E. STRESEMANN From the Asthmapoliklinik, Free University, West Berlin, Germany (Received May 14, 1963) The dose/response curves for the protective effects of the new antihistamine compounds trimeprazine, 10-(3-diethylamino-2-methylpropyl)phenothiazine 1,1-dioxide hydrochloride (oxomemazine hydrochloride), cyproheptadine, homochlorcyclizine and methotrimeprazine against the anaphylactic microshock of the guinea-pig were similar to that of promethazine. The first three compounds, however, protected at lower doses than promethazine (5 to 10 ug/kg). The protective effect of cyproheptadine lasted longer than 24 hr. The antianaphylactic effects of promethazine, mepyramine, chlorcyclizine, tri- pelennamine and diphenhydramine have been investigated by Armitage, Herxheimer & Rosa (1952). In this paper we describe investigations of a few of the newer antihistamines. METHODS The microshock method (Herxheimer, 1952) was used and the protection against anaphylactic shock was calculated according to Armitage et al. (1952) with the formula p=100(1-c/t), in which p is the percentage of full protection, c the control preconvulsion time and t the preconvulsion time of the animal under the influence of the drug. The compounds investigated were trimeprazine, methotrimeprazine, cyproheptadine, homo- chlorcyclizine and 10(-3-diethylamino-2-methylpropyl)phenothiazine 1,1-dioxide hydrochloride (oxomemazine hydrochloride, 6847 R.P.). They were injected intramuscularly in aqueous solution; the exposure to the antigen (an aerosol of 5% albumen solution) was done 1 hr later. For cyproheptadine, the exposure was delayed by between 1 and 48 hr in order to investigate the duration of the effect.
    [Show full text]
  • Hygroscopicity of Pharmaceutical Crystals
    HYGROSCOPICITY OF PHARMACEUTICAL CRYSTALS A DISSERTATION SUBMITTED TO THE FACULTY OF GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY DABING CHEN IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY RAJ SURYANARAYANAN (ADVISER) JANUARY, 2009 © Dabing Chen, January / 2009 ACKNOWLEDGEMENTS I am very grateful to my thesis advisor, Prof. Raj Suryanarayanan, for his constant guidance, support, and encouragement throughout my research. Without his help, the completion of this thesis would be impossible. His friendship and advices are precious to my professional and personal growth and will help me overcome many difficulties in my future career. I would like to take the opportunity to thank Prof. David J.W. Grant, who was my advisor during the first three years in graduate school and led me into the research area of physical pharmacy. It was my great honor to have worked for him, and he will always live as a role model in my life. Many thanks to Dr. Zheng Jane Li at Boehringer Ingelheim Pharmaceuticals (BI) for her invaluable advice as an industrial mentor and also for agreeing to serve on my committee. I sincerely appreciate her helpful discussions, revision of the manuscripts, and supervision of my research. I also want to thank her for providing me the internship opportunity at BI. I thank Dr. Timothy S. Wiedmann and Dr. Theodore P. Labuza for serving on my committee and for critically reviewing my thesis. I also want to thank Dr. Timothy S. Wiedmann for allowing me the use of the HPLC instruments in his lab and also for his advice as the Director of Graduate Studies.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Proposed Regulation of the State Board of Pharmacy
    PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R133-14 Workshop July 24, 2014 NAC 453.540 Schedule IV. (NRS 453.146, 639.070) 1. Schedule IV consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated. 2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, including, without limitation, their salts, calculated as the free anhydrous base of alkaloid, is hereby enumerated on schedule IV, in quantities: (a) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; or (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxy- butane). 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated on schedule IV, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: Alprazolam; Barbital; Bromazepam; Butorphanol; Camazepam; Carisoprodol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clobazam; Clonazepam; Clorazepate; Clotiazepam; Cloxazolam; Delorazepam; Diazepam; Dichloralphenazone; Estazolam; Ethchlorvynol; Ethyl loflazepate; Fludiazepam; Flunitrazepam; --1-- Agency Draft of Proposed Regulation R133-14 Flurazepam; Halazepam; Haloxazolam; Ketazolam; Loprazolam; Lorazepam; Lormetazepam; Mebutamate; Medazepam; Meprobamate; Methohexital; Methylphenobarbital (mephobarbital); Midazolam; Nimetazepam; Nitrazepam; Nordiazepam; Oxazepam; Oxazolam; Paraldehyde; Petrichloral; Phenobarbital; Pinazepam; Prazepam; Quazepam; Tramadol (2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol) Temazepam; Tetrazepam; Triazolam; Zaleplon; Zolpidem; or Zopiclone.
    [Show full text]
  • Comparative Efficacy and Acceptability of Pharmacological Treatments for Insomnia in Adults: a Systematic Review and Network Meta-Analysis (Protocol)
    Cochrane Database of Systematic Reviews Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis (Protocol) De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L. Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-anal- ysis. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No.: CD012364. DOI: 10.1002/14651858.CD012364. www.cochranelibrary.com Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta- analysis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 4 METHODS ...................................... 4 Figure1. ..................................... 5 ACKNOWLEDGEMENTS . 9 REFERENCES ..................................... 10 APPENDICES ..................................... 14 WHAT’SNEW..................................... 18 CONTRIBUTIONSOFAUTHORS . 18 DECLARATIONSOFINTEREST . 18 Comparative efficacy and acceptability of pharmacological treatments for
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Antiglaucoma Compositions Containing Combinations of Alpha-2 Agonists and Beta-Blockers
    ~" ' MM II II II MM II II II Ml II II I II J European Patent Office _ _ _ © Publication number: 0 365 662 B1 Office europeen* des.. brevets , © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 09.03.94 © Int. CI.5: A61 K 31/47 © Application number: 89905874.7 @ Date of filing: 26.04.89 © International application number: PCT/US89/01994 © International publication number: WO 89/10126 (02.11.89 89/26) (54) ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF ALPHA-2 AGONISTS AND BETA-BLOCKERS. ® Priority: 26.04.88 US 186504 1075-1078 @ Date of publication of application: J. of Cardiovascular Pharmacology, vol. 2, 02.05.90 Bulletin 90/18 suppl. 1, 1980, S. 21-28 © Publication of the grant of the patent: © Proprietor: ALCON LABORATORIES INC 09.03.94 Bulletin 94/10 6201 South Freeway Ft. Worth, TX 76134(US) © Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE @ Inventor: DE SANTIS, Louis, M. 2316 Wlnton Terrace West © References cited: Fort Worth, TX 761 09(US) US-A- 4 455 317 US-A- 4 515 800 © Representative: Jump, Timothy John Simon et AM A DRUG EVALUATION, 2nd ed., 1973; al "Agent used to treat Glaucoma", pp. 675-686. Venner Shipley & Co. 20 Little Britain GLAUCOMA, vol. 1, no. 1, February 1979; London EC1A 7DH (GB) 00 S.SUGAR, pp. 9-15. CM CO Ophthalmology, vol. 96, no. 1, 1989, p. 3-7 CO m Ophthalmology, vol. 98, no. 7, 1991, p. CO 00 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]